Alkem Laboratories receives classification letter from USFDA for its St. Louis facility
15th May 2019

Alkem Laboratories has received a letter from the US Food and Drug Administration (USFDA) classifying the inspection conducted at its St. Louis facility as Official Action Indicated (OAI). The Company will not have any significant impact on existing supplies or the existing revenues from the operations of this facility.

Earlier, USFDA had conducted Inspection at the company’s manufacturing facility located at St. Louis, USA dated on February 06, 2019 and March 22, 2019.

Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.